Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 15.19 Billion | USD 25.19 Billion | 5.78% | 2023 |
According to a report from Zion Market Research, the global Calcium Channel Blocker Market was valued at USD 15.19 Billion in 2023 and is projected to hit USD 25.19 Billion by 2032, with a compound annual growth rate (CAGR) of 5.78% during the forecast period 2024-2032.
This report explores market strengths, weakness, opportunities, and threats. It also provides valuable insights into the market's growth drivers, challenges, and the future prospects that may emerge in the Calcium Channel Blocker Market industry over the next decade.
Calcium channel blockers are a type of medications that lower the blood pressure by preventing calcium from entering the cells of your heart and arteries. Calcium causes the heart and arteries to contract more strongly. By blocking Calcium, calcium channel blockers allow blood vessels to relax and open, thereby increase the supply of blood and oxygen to the heart. Doctor generally prescribe a calcium channel blocker to treat high blood pressure. These drugs are also used to cure chest pain, coronary heart disease, an irregular heartbeat. These drugs also prevent migraine headaches. Scientists are currently exploring other potential uses for calcium channel blockers. For example, by reducing high blood pressure, calcium channel breakers may be able to lower the risk of Alzheimer’s disease. Get information on Alzheimer’s Drugs Market.
Changing lifestyle of people across all regions is leading to an increase in the number of stress related diseases or cardiovascular diseases, which is a major factor, which in turn is anticipated to boost the calcium channel blocker market growth.
The global Calcium Channel Blocker market has witnessed a very slight decline due to the lockdown enforcement placed by governments in order to contain COVID spreading. The restrictions imposed by various nations to contain COVID had stopped the production, resulting in a disruption across the whole supply chain. However, the global markets are slowly opening to their full potential and there's a surge in demand of calcium channel blocker. The market would remain bullish in upcoming year.
The significant decrease in the global Calcium Channel Blocker market size in 2020 is estimated on the basis of the COVID-19 outbreak and its negative impact on the economies and industries across the globe. Various scenarios have been analyzed on the basis of inputs from various secondary sources and the current data available about the situation.
Change in the lifestyle of people across the world likely to augment the hypertension and stress related diseases, which in turn anticipated to drive the growth of the Calcium Channel Blocker market. Calcium Channel Blocker are the drugs that are used against hypertension and chest pain. It slows the calcium movement that helps to widen the blood vessels, thereby reducing blood pressure and makes it easier for the heart to pump the blood. According to World Health Organization, approximately 1.13 billion of people globally have hypertension. Also, Cardiovascular diseases are one of the leading causes of the death. Calcium Channel Blocker are effective against these indications. This increased in demand is likely to spur the growth of Calcium Channel Blocker market. However, the side effects of headache, rapid heart rate, and constipation are likely to hamper the overall demand for calcium channel blocker market.
Drug Class Segment Analysis Preview
Calcium channel blocker market is segmented into two types: Dihydropyridine and Non-Dihydropyridine. Dihydropyridine is one of the important groups of calcium channel blocker, which held approximately 63.2% of the overall market in 2020. Dihydropyridine class is expected to be the largest segment in the market due to growing demand from pharmaceutical industry. Lower cost and easy availability of the products is expected to propel the growth of Dihydropyridine segment. Dihydropyridine class of CCB market is further sub-segmented into Amlodipine, Cilnidipine, Felodipine, Verapamil, Diltiazem, Isradipine, Nicardipine, Nisoldipine, Nifedipine, and others. Whereas, the Non-Dihydropyridine market is sub-segmented into Diltiazem and Verapamil.
Application Segment Analysis Preview
The market is segmented into five types: the calcium hypertension, angina pectoris, pregnancy, anti-obesity and other. Hypertension segment hold the major share in the calcium channel blocker market in 2020. For instance, in hypertension, Verapamil and Amlodipine are increasingly used in the pharmaceutical industry. Amlopdipine is a first line therapy for the treatment obesity, angina pectoris and others.
Report Attributes | Report Details |
---|---|
Report Name | Calcium Channel Blocker Market |
Market Size in 2023 | USD 15.19 Billion |
Market Forecast in 2032 | USD 25.19 Billion |
Growth Rate | CAGR of 5.78% |
Number of Pages | 140 |
Key Companies Covered | Pfizer Inc., AstraZeneca Plc., Bayer Healthcare LLC., GlaxoSmithKline Plc., Sanofi S.A., Johnson & Johnson, Abcam, AbMole Bioscience, and Clearsynth |
Segments Covered | By Drugs Class, By Application and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
Based on geography, calcium channel blocker market segmented into five major regions: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America accounted for the largest share in the market in terms of consumption. Rising percentage of obese and hypertension patient population in Asia Pacific is expected to prompt the growth of calcium channel blocker market within the forecast period.
Major market players of Calcium Channel Blocker market comprise:
By Drugs Class
By Application
By Region
FrequentlyAsked Questions
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed